Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for THALOMID
- Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
- Thalidomide Maintenance Treatment in DLBCL
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- Conmana Combined With Thalidomide to Treat NSCLC
- Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
- Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
- Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
- Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis
- Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
- Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
- Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
- Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
- Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
- Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma
- Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
- Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
- Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis
- Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
- Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)
- Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
- UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
- Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
- Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
- Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
- Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
- Biochemotherapy With Temozolomide for Metastatic Melanoma
- Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis
- R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
- Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
- Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
- GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
- Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome
- Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
- Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
- Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
- Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
- Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
- Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
- Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm,
- DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
- UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
- Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
- Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
- Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
- Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
- Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
- Thalidomide for Multiple Myeloma
- Thalidomide-Dexamethasone for Multiple Myeloma
- Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
- Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
- Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
- Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
- Thalidomide in Treating Patients With Myelodysplastic Syndrome
- Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
- Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
- Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
- S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
- Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
- Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
Clinical trials list
click for details